Yakult Of Japan To Introduce Liver Cancer Drug From U.S. Firm Celsion
This article was originally published in PharmAsia News
Executive Summary
Yakult announced Aug. 19 that the company and U.S. bioventure company Celsion executed a letter of intent relating to the commercialization of liver cancer drug ThermoDox for the Japanese markets. Yakult will start preclinical and clinical studies required for approval in Japan. The amount of payment and market rights are subject to a definitive agreement. Currently in final development in the U.S, Canada and Italy, the drug is estimated to be approved overseas as early as 2010. Yakult has focused on increasing its healthcare division to 10 percent of the company's business in 2008. (Click here for more - Japanese language
|
Yakult announced Aug. 19 that the company and U.S. bioventure company Celsion executed a letter of intent relating to the commercialization of liver cancer drug ThermoDox for the Japanese markets. Yakult will start preclinical and clinical studies required for approval in Japan. The amount of payment and market rights are subject to a definitive agreement. Currently in final development in the U.S, Canada and Italy, the drug is estimated to be approved overseas as early as 2010. Yakult has focused on increasing its healthcare division to 10 percent of the company's business in 2008. (Click here for more - Japanese language) "Yakult Reaches Agreement With American Bioventure On Commercialization of Cancer Drug" - Sankei News (8/19/08) |